



The Canadian Association of Pharmacy in Oncology Presents

CAPhO Oncology Fundamentals Day
Saturday, September 30, 2017





Accreditation



CAPhO Oncology Fundamentals Day is accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for **5.50 continuing education credits (CEUs)**. Participation on September 30th is required to receive a letter of participation.


CCCEP Number: 1152-2017-2157-C-P and 1152-2017-2158-C-T

Program at a Glance

Click on the session title or presenter name to go directly to the session description or presenter biography.

Note: All times indicated are Eastern Daylight Times (EDT). The program below is subject to change.

Time	Session
10:00 – 10:10	Welcome Remarks
10:10 – 10:40	Cancer Screening – <i>Danica Wasney, CancerCare Manitoba, Winnipeg, MB</i>
10:40 – 11:25	Prostate Cancer – <i>Gerry Mills, Valley Regional Hospital, Kentville, NS</i>
11:25 – 12:10	Gynecological Cancers – <i>Michelle Deschamps, Saskatchewan Cancer Agency, Saskatoon, SK</i>
12:10 – 12:25	<i>Break</i>
12:25 – 12:55	Myeloproliferative Neoplasms – <i>Kyla Marien, Tom Baker Cancer Centre, Calgary, AB</i>
12:55 – 13:40	Bone Marrow Transplant – <i>Nikki Blosser, Tom Baker Cancer Centre, Calgary, AB</i>
13:40 – 14:10	<i>Break</i>
14:10 – 14:40	Complementary Medicines & Cancer – <i>Scott Gavura, Cancer Care Ontario, Toronto, ON</i>
14:40 – 15:25	Cancer Pain Management – <i>Diane Brideau-Laughlin, Horizon Health Network, Moncton, NB</i>
15:25 – 15:55	Immunotherapy Toxicity Management – <i>Tom McFarlane, University of Waterloo, Kitchener, ON</i>
15:55 – 16:25	Oncologic Emergencies – <i>Jason Wentzell, The Ottawa Hospital, Ottawa, ON</i>
16:25 – 16:35	Closing Remarks



Session Descriptions and Presenter Biographies

Cancer Screening - Danica Wasney, CancerCare Manitoba, Winnipeg, MB

Cancer screening programs are designed to improve patient outcomes through earlier detection of cancer diagnoses. These programs are based on evidence of reduced cancer specific mortality, and that the benefits of screening outweigh harms at the population level.

While a number of cancers have evidence-based recommendations to guide screening strategies, the majority of cancers do not have routine screening recommendations. Cancer screening requires a balance of appropriate use of health system resources/evidence as well as patient specific factors. Screening and follow up for the individual patient may vary depending on clinical judgment and/or available resources.

This presentation will explore issues related to cancer screening, including a review of current screening recommendations for breast cancer, cervical cancer, colon cancer, lung cancer, and prostate cancer. Current controversies surrounding cancer screening will also be discussed. Lastly, the pharmacist's potential role in cancer screening will be explored.

Learning Objectives:

1. Discuss which cancers have evidence-based screening recommendations and programs; and
2. Discuss controversies surrounding cancer screening at both the patient-specific and population level.



Danica Wasney is a Clinical Pharmacist for the Provincial Oncology Drug Program at CancerCare Manitoba. She recently completed 6 years as a member of the Expert Review Committee for the pan-Canadian Oncology Drug Review (pCODR) at the Canadian Agency for Drugs and Technologies in Health (CADTH).

She graduated from the Faculty of Pharmacy at University of Manitoba and completed an Accredited Hospital Pharmacy Residency at The Ottawa Hospital.

She is a Board Certified Oncology Pharmacist, a member of the CAPhO Research Committee, and a past member of the CAPhO Education Committee.

[Back to Program at a Glance](#)



Prostate Cancer - Gerry Mills, Valley Regional Hospital, Kentville, NS

A brief review of pathology and treatment of prostate cancer for oncology pharmacists.

Learning Objectives:

1. Give a brief review of pathology & staging of Prostate cancer;
2. Review therapies at various stages of disease with a brief review of clinical data for the various treatment modalities;
3. Discuss expected outcomes of treatment modalities in terms of response and toxicities; and,
4. Review the prevention, monitoring and treatment of adverse effects associated with the various individual treatments.

Gerry Mills attended Memorial University in St. John's, NL working towards his BSc in physics before deciding to study Pharmacy in 1982. After graduating he worked as a community pharmacist in St. John's, before switching to hospital pharmacy in 1989. He has been a clinical oncology pharmacist for the past 10 years at the Valley Regional Hospital in Kentville, NS. He splits his time between the Pharmacy Department and the Chemotherapy/Oncology clinic performing pharmacy assessments, medication reviews, and patient and staff education and follows up toxicity assessment for intravenous and oral chemotherapy patients in the outpatient setting.

Gerry's main interest in oncology include direct patient counseling and providing current evidence informed information to ensure health care team members are best able to manage and prevent chemotherapy related toxicities. He also has a personal interest in furthering his education in oncology, particularly in regards to the use of targeted therapies.

[Back to the Program at a Glance](#)



Gynecological Cancers - Michelle Deschamps, Saskatchewan Cancer Agency, Saskatoon, SK

This presentation will provide an overview on the epidemiology and clinical presentation of epithelial ovarian, cervical and endometrial cancers, which are the most commonly encountered gynecological cancers. We will then discuss management strategies including surgery and radiation therapy with our focus mainly on drug therapies. We will also highlight the pharmacist's role in supportive care and symptom management.

Learning Objectives:


1. Identify the common adjuvant (curative) strategies for early stage ovarian, cervical and endometrial cancers;
2. Describe the first line treatment options for advanced ovarian, cervical and endometrial cancers;
3. Discuss the role of hormone and targeted therapies in gynecological cancers; and
4. Develop symptom management plans for patients undergoing treatment.



Michelle Deschamps obtained her pharmacy degree at the University of Saskatchewan in 1989 and returned to complete a Master's degree in 2002. Michelle has worked in a variety of practice settings including community pharmacy, hospital pharmacy, the Canadian Armed Forces, and the University of Saskatchewan College of Pharmacy and Nutrition conducting practice-based research.

Michelle joined the Saskatchewan Cancer Agency in 2009 and is currently a Senior Oncology Pharmacist. She is a member of multidisciplinary teams in Radiation Therapy Reviews and Pain/Symptom Management at the Saskatoon Cancer Clinic.

[Back to the Program at a Glance](#)



Myeloproliferative Neoplasms - Kyla Marien, Tom Baker Cancer Centre, Calgary, AB

Myeloproliferative neoplasms are a group of rare diseases that are characterized by overproduction of one or more blood cell lines in the bone marrow. These blood disorders are usually slow progressing, and treatment goals are to control symptoms, improve quality of life, and to slow progression of disease. There are a number of myeloproliferative neoplasms that work in different ways, the most common being chronic myelogenous leukemia (CML), Essential Thrombocytosis (ET), Polycythemia Vera (PV), and Myelofibrosis.


Learning Objectives:

1. Define the three common non-Philadelphia chromosome myeloproliferative neoplasms: Essential thrombocytosis, Polycythemia Vera, and Myelofibrosis;
2. Identify the different signs and symptoms associated with each neoplasm;
3. Treatment options in managing symptoms and controlling each disease; and
4. Pharmacist's role in supportive care, patient education, and monitoring.



Kyla Marien graduated from University of Saskatchewan in 2003 and currently works for Alberta Health Services at the Tom Baker Cancer Centre as clinical hematology pharmacist. Over the past 13 years she has practiced in many diverse settings, including community, geriatrics, hospital outpatient, and oncology. Kyla truly believes each setting provided her with different skills and knowledge to allow her to practice today in oncology with an appreciation for a patient's experiences both in the center and in the community. Before joining the hematology clinical pharmacy team, Kyla developed her oncology clinical skills with the oral chemotherapy management clinic. Kyla is a proud CAPhO member.

[Back to the Program at a Glance](#)



Bone Marrow Transplant - Nikki Blosser, Tom Baker Cancer Centre, Calgary, AB

Hematopoietic stem cell transplant is a modality of treatment for many hematological malignancies. Although it can offer significant disease control and in some cases, a cure, it comes with a significant risk of morbidity. This presentation will focus on the care required in the post-transplant setting to optimize outcomes. It will discuss medications used to minimize the long term impact this treatment will have on patient's quality of life and will highlight how pharmacists can help manage the toxicities from this treatment.


Learning Objectives:

1. Identify the different types of hematopoietic stem cell transplant and indications for each;
2. Describe graft versus host disease (GVHD) and its risk in the post-allogeneic transplant setting;
3. Discuss the immunosuppressant medications used to minimize the risk of GVHD;
4. Review antimicrobial prophylaxis and the medications used at various intervals post-transplant; and
5. Discuss other supportive care measures required in this patient population.



Nikki Blosser graduated from Memorial University of Newfoundland School of Pharmacy in 2010 and then moved to Calgary to complete an Accredited Canadian Residency Program with a focus in oncology. For the past six years she has been working as a clinical pharmacist in the Blood and Marrow Transplant Program at the Tom Baker Cancer Centre. She continues to precept Cancer Care pharmacy residents in their BMT rotations. She obtained an Advanced Prescribing Authority (APA) in 2013 and helped implement the pharmacist-led therapeutic drug monitoring role in the BMT clinic. She is a past member of the CAPhO Communications committee and currently a member of the planning committee for the allied health sessions of the annual Canadian Conference on Lymphoproliferative Disorders (CCOLD).

[Back to the Program at a Glance](#)



Complementary Medicines and Cancer - Scott Gavura, Cancer Care Ontario, Toronto, ON

The interest and use of complementary and/or alternative medicine as part of, or instead of, “conventional” cancer care, appears to be growing. While patients often seek out CAM independently, its use may also be endorsed by health professionals, regulators, and health care organizations that believe that CAM has something to offer cancer patients. With the growing interest in CAM, it is essential for oncology pharmacists to understand the rationale for CAM, the evidence base for CAM, the implications to cancer care, and best practices in dialogue with patients to support informed, collaborative decision-making and ethical, science-based care.


Learning Objectives:

1. Understand why CAM is popular, and why cancer patients may seek out CAM;
2. Understand the evidence base for CAM;
3. Understand problems and risk of CAM use in cancer care;
4. Understand the clinical outcomes of patients that use CAM; and
5. How to talk to patients about CAM.



Scott Gavura is Director, Provincial Drug Reimbursement Programs at Cancer Care Ontario. In this position Scott is responsible for the strategic management of CCO's cancer reimbursement programs. Scott is a registered pharmacist and has a Bachelor of Science in Pharmacy degree and an MBA from the University of Toronto.

[Back to the Program at a Glance](#)



Cancer Pain Management - Diane Brideau-Laughlin, Horizon Health Network, Moncton, NB

Pain is a common complication of many incurable diseases such as cancer, end-stage heart disease, lung diseases and motor neuron diseases. Up to 85% of patients with advanced cancer will experience pain. Failure to manage this symptom results in suffering and poor quality of life.

The aim of this presentation is to help you acquire some basic principles of pain management.


Learning Objectives:

1. Understand the concept of total pain;
2. Initiate an analgesic regimen;
3. Understand the basic principles of analgesic titration;
4. Manage common opioid-related adverse events; and
5. Switch from one opiate to another.



Diane Brideau-Laughlin graduated with a BSc in Pharmacy from the College of Pharmacy, Dalhousie University and an MSc in Health Technology Assessment (HTA) from l'Université de Montréal. During her career as a hospital pharmacist she has worked in various areas but primarily as a drug information and drug use evaluation pharmacist and later as Regional Lead for health technology assessment for Horizon Health Network. Most recently she was Clinical Pharmacy Specialist, Palliative Care and currently works with the pharmacist team in the Dr. Sheldon H. Rubin Oncology Clinic at The Moncton Hospital.

[Back to the Program at a Glance](#)



Immunotherapy Toxicity Management - Tom McFarlane, University of Waterloo, Kitchener, ON

Checkpoint inhibitors are rapidly becoming more prevalent in oncology treatment of various malignancies and have the potential to transform cancer care by conferring long-term survival in scenarios where treatment options have traditionally been very limited. However, these agents carry with them the potential for immune-mediated adverse effects requiring very specific management. These adverse effects have the potential for misdiagnosis and mismanagement, and it is up to us as clinicians to ensure that patients are properly educated about reporting them, and also to keep other members of the patient's healthcare team apprised of what to do when a patient on checkpoint inhibition presents with toxicity. This presentation will delve into the different adverse effects that patients may experience on checkpoint inhibitor treatment, and give practical examples of how to manage potential toxicity from these agents.


Learning Objectives:

1. Understand the mechanistic basis behind the development of adverse effects with checkpoint inhibition;
2. Recognize potential adverse effects of treatment with checkpoint inhibitors; and
3. Manage adverse effects of checkpoint inhibitors when they occur.



Dr. Tom McFarlane is Clinical Lecturer and researcher at the University of Waterloo School of Pharmacy in Kitchener, Ontario, where he created, coordinates, and teaches the oncology portion of the curriculum in the Doctor of Pharmacy program. He is also an oncology pharmacist at Odette Cancer Centre in Toronto, Ontario.

[Back to the Program at a Glance](#)



Oncologic Emergencies - Jason Wentzell, The Ottawa Hospital, Ottawa, ON

Oncologic emergencies are not infrequent and can contribute to significant morbidity and mortality in patients with a wide range of underlying malignancies. Symptoms associated with certain oncologic emergencies may be an initial presenting symptom of an underlying malignancy and timely identification or recognition by a health care provider may help to ultimately improve patient outcomes. Pharmacists practice across a spectrum of professional roles, ranging from front-line care providers to specialized oncology practitioners and each requires a basic understanding of the physiologic principles of oncologic emergencies and the resulting therapeutic management strategies to ensure their patients receive appropriate care. This session will focus on the provision of information pertinent to pharmacy practitioners involved in the care of patients at risk of, or who are experiencing various oncologic emergencies.

Pertaining to common oncologic emergencies, this lecture will briefly detail; underlying mechanisms, highlight associated malignancies, describe characteristic symptoms and appropriate therapeutic management and monitoring. The lecture will focus on tumor lysis syndrome, hypercalcemia of malignancy and malignant spinal cord compression. Emphasis will be made to demonstrate the potential role of the pharmacist and relevant therapeutics, including areas of clinical controversy, will be highlighted. Lastly, a brief introduction to contributing paraneoplastic syndromes and a re-iteration of the role of emerging immunotherapies will be discussed in their context of potential oncologic emergencies.

Learning Objectives:

1. Participants will learn about the underlying mechanisms, associated malignancies, characteristic symptoms and appropriate therapeutic management and monitoring of the following oncologic emergencies:
 - a. Tumor lysis syndrome
 - b. Hypercalcemia of malignancy
 - c. Malignant spinal cord compression
2. Participants will receive a brief introduction to promote awareness and recognition into how paraneoplastic syndromes and immunotherapy may also contribute on oncologic emergencies



Jason Wentzell completed his pharmacy degree at Dalhousie University and his Pharmacy Residency at The Ottawa Hospital. He has been practicing as an inpatient Medical Oncology pharmacist for 6 years and is a Board Certified Oncology Pharmacist. Jason is the pharmacist representative in the Ottawa Hospital Cardio-Oncology clinic and is involved in research in the areas of cardio-oncology, integration of pharmacy learners into practice, simulation education, oral anticancer therapy and clinical key performance indicators for pharmacists. He is currently the local pharmacist representative for the CAPhO 2018 Conference in Ottawa and is a Regional Clinical Coordinator for the University of Waterloo PharmD program.

[Back to the Program at a Glance](#)